Publikationen in Zusammenarbeit mit Forschern von Columbia University (39)

2024

  1. p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway

    Cell Reports Medicine, Vol. 5, Núm. 2

2023

  1. Author Correction: γ-Linolenic acid in maternal milk drives cardiac metabolic maturation (Nature, (2023), 618, 7964, (365-373), 10.1038/s41586-023-06068-7)

    Nature

  2. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

    British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294

  3. γ-Linolenic acid in maternal milk drives cardiac metabolic maturation

    Nature, Vol. 618, Núm. 7964, pp. 365-373

2022

  1. Guiding the global evolution of cytogenetic testing for hematologic malignancies

    Blood, Vol. 139, Núm. 15, pp. 2273-2284

2021

  1. Author Correction: c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis (Nature Metabolism, (2020), 2, 11, (1350-1367), 10.1038/s42255-020-00306-2)

    Nature Metabolism

  2. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

    British Journal of Haematology, Vol. 194, Núm. 3, pp. 496-507

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

    Blood Cancer Journal, Vol. 11, Núm. 12

  5. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e119-e130

  6. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2020

  1. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk

    Journal of Hematology and Oncology, Vol. 13, Núm. 1

  2. c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis

    Nature Metabolism, Vol. 2, Núm. 11, pp. 1350-1367

2019

  1. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312

  2. Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma ¨

    Journal of Clinical Oncology

2018

  1. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR

    Haematologica, Vol. 103, Núm. 12, pp. 2079-2087

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd

    Nature Communications, Vol. 7

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  4. Heterogeneity of psychosis risk within individuals at clinical high risk: A meta-analytical stratification

    JAMA Psychiatry, Vol. 73, Núm. 2, pp. 113-120